Olema Pharmaceuticals, Inc. (OLMA)
OLMANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$7.36
+0.0300 (+0.41%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $643.98m
- P/E
- –
- EPS, last 4 quarters
- $-2.12
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.24 to $36.26
- Average volume
- 1.26m
- Previous close
- $7.33
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $33.43, +354.2% from here
Earnings
next estimate $-0.6000Next report
Sep 2025
-11.4%
Dec 2025
+2.0%
Mar 2026
0.0%
Jun 2026
-15.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$45.88m | -$50.08m | -$57.99m | -$67.18m |
| Net income | -$42.22m | -$46.06m | -$53.09m | -$63.20m |
News
8 latest- The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyZacks · Oct 19, 2026
- 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks · Oct 16, 2026
- Olema Appoints Jason O'Byrne As CFO RTTNews · Aug 13, 2026
- Wolfe Research Initiates Coverage of Olema Pharmaceuticals (OLMA) with Peer Perform RecommendationFintel · Mar 27, 2026
- Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?The Motley Fool · Mar 22, 2026
- Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · Mar 18, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchThe Motley Fool · Mar 16, 2026
- Notable Monday Option Activity: CRWD, OLMA, COFBNK Invest · Mar 9, 2026
The company
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- olema.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.